{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:22:59Z","timestamp":1787930579114,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund","award":["2023A1515220024"],"award-info":[{"award-number":["2023A1515220024"]}]},{"DOI":"10.13039\/501100003785","name":"Medical Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024070"],"award-info":[{"award-number":["2024070"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Hospital Pharmaceutical Research Fund project funding","award":["2024A31"],"award-info":[{"award-number":["2024A31"]}]},{"name":"Research Funds from Guangzhou Panyu Central Hospital","award":["PY-2023-007, PY-2023-010, and PY-2023-026"],"award-info":[{"award-number":["PY-2023-007, PY-2023-010, and PY-2023-026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01203-2","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:53:37Z","timestamp":1787302417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and bioequivalence study of enteric-coated omeprazole capsule in healthy Chinese subjects under fasting and fed conditions"],"prefix":"10.1186","volume":"27","author":[{"given":"Fucai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","volume":"390","author":"A Lanas","year":"2017","unstructured":"Lanas A, Chan FKL. Peptic ulcer disease. Lancet (London England). 2017;390:613\u201324.","journal-title":"Lancet (London England)"},{"key":"1203_CR2","doi-asserted-by":"crossref","unstructured":"Sverd\u00e9n E, Agr\u00e9us L, Dunn JM, Lagergren J. Peptic ulcer disease. BMJ. 2019;367.","DOI":"10.1136\/bmj.l5495"},{"key":"1203_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000505367","volume":"38","author":"P Malfertheiner","year":"2020","unstructured":"Malfertheiner P, Schulz C. Peptic Ulcer: Chapter Closed? Dig Dis (Basel Switzerland). 2020;38:112\u20136.","journal-title":"Dig Dis (Basel Switzerland)"},{"key":"1203_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11894-015-0452-2","volume":"17","author":"H Yandrapu","year":"2015","unstructured":"Yandrapu H, Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015;17:24.","journal-title":"Curr Gastroenterol Rep"},{"key":"1203_CR5","doi-asserted-by":"crossref","unstructured":"Jaiswal F, Rai AK, Wal P, Wal A, Singh SP. Peptic ulcer: a review on etiology, pathogenesis and treatment. Asian J Pharm Educ Res. 2021;10(4):1.","DOI":"10.38164\/AJPER\/10.4.2021.1-17"},{"key":"1203_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00002512-199609040-00003","volume":"9","author":"M Lazzaroni","year":"1996","unstructured":"Lazzaroni M, Porro GB. Treatment of Peptic Ulcer in the Elderly: Proton Pump Inhibitors and Histamine H 2 Receptor Antagonists. Drugs aging. 1996;9:251\u201361.","journal-title":"Drugs aging"},{"key":"1203_CR7","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36303\/SAJAA.2020.26.6.S3.2558","volume":"26","author":"KD Pegu","year":"2020","unstructured":"Pegu KD. Pharmacology of antacids. South Afr J Anaesth. 2020;26:S133\u2013136.","journal-title":"South Afr J Anaesth"},{"key":"1203_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528\u201334.","journal-title":"Curr Gastroenterol Rep"},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"e000204","DOI":"10.32892\/jmri.204","volume":"4","author":"MH Tanveer","year":"2020","unstructured":"Tanveer MH, Tanveer MS, Ali MH, Javed M. Omeprazole vs Lansoprazole in the Management of Gastroesophageal Reflux Disease: A Systematic Literature Review. J Med Res Innov. 2020;4:e000204\u2013000204.","journal-title":"J Med Res Innov"},{"key":"1203_CR10","doi-asserted-by":"crossref","unstructured":"Ouyang Zhang, Xu Z. Research progress on omeprazole in the treatment of peptic ulcers. MEDS Clin Med. 2024;5.","DOI":"10.23977\/medsc.2024.050303"},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40360-020-00433-2","volume":"21","author":"D Ochoa","year":"2020","unstructured":"Ochoa D, Roman M, Cabaleiro T, Saiz-Rodriguez M, Mejia G, Abad-Santos F. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. BMC Pharmacol Toxicol. 2020;21:54.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1203_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/9990554","volume":"2024","author":"M Prasad Vg","year":"2024","unstructured":"Prasad Vg M, McFarland LV, Thacker HP, Puri R, Lawate PS, Li Z. Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis. Int J Clin Pract. 2024;2024:1\u201313.","journal-title":"Int J Clin Pract"},{"key":"1203_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJM199104043241406","volume":"324","author":"N Maton Paul","year":"1991","unstructured":"Maton Paul N. Omeprazole. N Engl J Med. 1991;324:965\u201375.","journal-title":"N Engl J Med"},{"key":"1203_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0889-8553(05)70093-5","volume":"28","author":"JG Hatlebakk","year":"1999","unstructured":"Hatlebakk JG, Katz PO, Castell DO. Medical therapy: management of the refractory patient. Gastroenterol Clin N Am. 1999;28:847\u201360.","journal-title":"Gastroenterol Clin N Am"},{"key":"1203_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5414\/CPP47023","volume":"47","author":"SY Rhim","year":"2009","unstructured":"Rhim SY, Park JH, Park YS, Lee MH, Hwang KG, Kim YS, Shaw LM, Lee YS, Kang JS. Pharmacokinetics and bioequivalence of 20\u00a0mg omeprazole capsule in 24 healthy Korean male volunteers. Int J Clin Pharmacol Ther. 2009;47:23\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1203_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2165\/00044011-200525060-00004","volume":"25","author":"M Vaz-da-Silva","year":"2005","unstructured":"Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcao A, Silveira P, Almeida L. Soares-da-Silva P: Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig. 2005;25:391\u20139.","journal-title":"Clin Drug Investig"},{"key":"1203_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2165\/00003088-199120010-00003","volume":"20","author":"CW Howden","year":"1991","unstructured":"Howden CW. Clinical Pharmacology of Omeprazole. Clin Pharmacokinet. 1991;20:38\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","volume":"134","author":"M Koziolek","year":"2019","unstructured":"Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, et al. The mechanisms of pharmacokinetic food-drug interactions \u2013 A perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31\u201359.","journal-title":"Eur J Pharm Sci"},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00044011-200121030-00006","volume":"21","author":"M Vaz-da-Silva","year":"2001","unstructured":"Vaz-da-Silva M, Hainzl D, Almeida L, Dolgner A, Silveira P, Maia J, Soares-da-Silva P. Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers. Clin Drug Investig. 2001;21:203\u201310.","journal-title":"Clin Drug Investig"},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/cts.13255","volume":"15","author":"S Zhou","year":"2022","unstructured":"Zhou S, Xie R, Zhang X, He X, Huang J, Jungang Y, Liao M, Ding Y, Yang D, Liu Y, et al. Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study. Clin Transl Sci. 2022;15:1439\u201348.","journal-title":"Clin Transl Sci"},{"key":"1203_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2165\/00003495-199142010-00008","volume":"42","author":"D McTavish","year":"1991","unstructured":"McTavish D, Buckley MMT, Heel RC. Omeprazole. Drugs. 1991;42:138\u201370.","journal-title":"Drugs"},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/pharmaceutics17020161","volume":"17","author":"S Ramesh","year":"2025","unstructured":"Ramesh S, Zvon\u00ed\u010dek V, P\u011b\u010dek D, Pi\u0161lov\u00e1 M, Ber\u00e1nek J, Hofmann J, Dumicic A. Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption. Pharmaceutics. 2025;17:161.","journal-title":"Pharmaceutics"},{"key":"1203_CR23","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.3390\/ph16121722","volume":"16","author":"H Helgadottir","year":"2023","unstructured":"Helgadottir H, Bj\u00f6rnsson ES. The impact of sex on the response to proton pump inhibitor treatment. J Pharmaceuticals. 2023;16:1722.","journal-title":"J Pharmaceuticals"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01203-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:43:58Z","timestamp":1787928238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01203-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01203-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical protocol received approval from the Ethics Committee of Drug Clinical Trials, Panyu District Central Hospital, Guangzhou, China(PYZXYYEC2022-004 and PYZXYYEC2022-003). This study was conducted in compliance with the Declaration of Helsinki (1989), Good Clinical Practice guidelines, and relevant local laws and regulations. Written informed consent was obtained from all participants prior to participation. Clinical trial registration number: CTR20221098 and CTR20220627.","order":1,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects in a clear and thorough manner, and their personal information was strictly protected from disclosure or public release.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}